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Infusion of angiotensin II reduces loss of glomerular capillary
area in the early phase of anti-Thy-1.1 nephritis possibly via
regulating angiogenesis-associated factors.
Background. Although angiotensin II (Ang II) is involved
in the progression of renal diseases, infusion of Ang II was re-
ported to surprisingly ameliorate the early phase of anti-Thy-1.1
nephritis (Wenzel et al, Kidney Int 61:1020, 2002). Considering
the known proangiogenic effect of Ang II and that angiogenic
glomerular capillary repair is required for the recovery of dam-
aged glomeruli in rat anti-Thy-1.1 nephritis, we hypothesized
that Ang II infusion starting prior to the initiation of nephritis
may induce the expression of angiogenic growth factors such as
vascular endothelial growth factor (VEGF) and angiopoietin-1
(Ang-1), resulting in the increased glomerular capillary area in
the early phase.
Methods. Ang II was infused (170 ng/min) in rats, and 5 days
later, nephritis was induced by the administration of mono-
clonal 1-22-3 antibodies. Ang II type 1 or type 2 receptor an-
tagonist (AT1R or AT2R, respectively) (losartan or PD123319,
respectively) was coadministered.
Results. Ang II infusion affected on neither the deposition
of Ig nor mesangiolysis in the initial phase, and resulted in the
aggravation of creatinine clearance at day 14 and 35 after initi-
ating anti-Thy-1.1 nephritis. Histologic alterations were amelio-
rated accompanied by reduced loss in rat endothelial cell anti-
gen (RECA)-1(+) endothelial area in Ang II–infused nephritic
rats on day 6 and 14 as compared to control nephritic group,
and nephritic alterations were mostly resolved on day 35 in
both groups. At the early stage (day 6), glomerular expression
of VEGF and receptors flk-1 and flt-1 as well as Ang-1, and
receptor Tie2 were increased, and glomerular monocyte infil-
tration and the expression of angiopoietin-2 (Ang-2), a natural
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antagonist of Ang-1, were reduced. Both Ang II receptors were
involved in the regulation of angiogenic factors and receptors.
Conclusion. These results demonstrate that infusion of ex-
ogenous Ang II starting prior to the induction of nephritis ac-
tivates VEGF and Ang-1 signaling regulated via both Ang II
receptors, potentially leading to the accelerated recovery of in-
jured glomerular endothelial cells in the early phase of anti-
Thy-1.1 nephritis. Increased expression of VEGF and Ang-1 on
podocytes further suggests the crucial association of endothelial
cells and podocytes in maintaining proper glomerular capillary
structures.
There are two major receptor isoforms for angiotensin
II (Ang II), type 1 receptor (AT1R) and type 2 receptor
(AT2R) [1]. AT1Rs are expressed in afferent and effer-
ent arterioles, glomeruli, and proximal tubules in normal
animals and humans [2]. The known biologic functions of
Ang II are exclusively mediated via AT1R according to
studies employing receptor-selective antagonists [1]. The
mechanisms of Ang II–induced renal injuries are gener-
ally attributed to vasoconstriction, growth promoting as
well as profibrotic effect leading to excess accumulation
of extracellular matrix (ECM). Experimental and clini-
cal studies using AT1R antagonist (AT1RA) or AT1aR–
deficient mice indicated the critical involvement of AT1R
in progressive renal disorders [3, 4].
Previous studies demonstrated the histologic abnor-
malities in renal arteries and arterioles accompanied
by the thickening of vessel walls similar to hyperten-
sive nephrosclerosis in angiotensinogen-deficient mice
[5] or in AT1a and AT1bR double knockout mice [6–8].
Blockade of AT1R signal in peri- and neonatal period
of spontaneously hypertensive rats (SHRs) results in
the formation of vascular lesions similar to malignant
hypertension [9]. In addition, activation of the renin-
angiotensin system (RAS) might possess beneficial ef-
fects on kidney in certain pathophysiologic conditions.
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For instance, blockade of the RAS resulted in exacer-
bated renal interstitial fibrosis of the stenosed kidney in a
renal artery stenosis model [10]. A salutary role for Ang
II was also demonstrated in a model of partial urinary
tract obstruction [11]. These studies thus suggest the dis-
tinct physiologic role of the RAS in the development and
maintenance of kidney apart from its known pathologic
functions.
The proliferation of mesangial cells and the expansion
of mesangial matrix are central features in various types
of glomerular disorders [12, 13]. Anti-Thy-1.1 nephritis
is one of the widely used models of mesangioprolifera-
tive glomerulonephritis [14]. Murine monoclonal 1-22-3
antibody binds to the mesangial cell surface and causes
proteinuria and histologic alterations characterized by
mesangiolysis followed by monocyte infiltration, mesan-
gial cell proliferation, and accumulation of mesangial
matrix [15]. Pharmacologic blockade of the RAS amelio-
rated the pathologic changes of the anti-Thy-1.1 nephri-
tis [16, 17]. However, recent study by Wenzel et al [18]
demonstrated that Ang II infusion starting 5 days prior
to the induction of anti-Thy-1.1 nephritis surprisingly re-
sulted in the amelioration of nephritic changes. Ang II
infusion induced a significant reduction in glomerular
monocyte infiltration, cell proliferation, and matrix ex-
pansion in nephritic rats compared to nephritic rats with-
out Ang II infusion at 5 days after the induction of nephri-
tis. In Ang II–infused nephritic rats, expression of mono-
cyte chemotactic protein-1 (MCP-1) was inhibited and
the glomerular expression of cell cycle inhibitor p27kip1
and of transforming growth factor-b (TGF-b) was in-
creased, potentially resulting in the amelioration of early
nephritic changes in this model [18].
Angiogenesis, the development of new blood vessels
from preexisting ones, is involved in physiologic events as
well as pathologic disorders, including tumor growth and
diabetic retinopathy [19]. Vascular endothelial growth
factor (VEGF) promotes endothelial cell proliferation,
migration, and tube formation and thus serves as a potent
inducer of angiogenesis [20]. VEGF also induces vascu-
lar permeability and endothelium-dependent vasodilata-
tion in association with endothelium-derived nitric oxide
[21]. In the early phase of anti-Thy-1.1 nephritis follow-
ing mesangiolysis, reduction in the number of glomerular
endothelial cells is observed, followed by the angiogenic
glomerular capillary repair process [22, 23]. The essen-
tial role of VEGF in promoting glomerular capillary re-
pair in anti-Thy-1.1 nephritis has been reported utilizing
VEGF165 aptamer [24]. Angiopoietin-1 (Ang-1), a major
physiologic ligand for Tie2 receptor, is responsible for
the recruitment and stable attachment of pericytes lead-
ing to the maturation of newly formed blood vessels [25].
Platelet-derived growth factor (PDGF) and TGF-b are
also known to play crucial roles in promoting pericyte
attachment [26, 27]. In contrast, angiopoietin-2 (Ang-2),
a natural antagonist of Ang-1, loosens the attachment
of pericytes rendering blood vessel to be “unstable” and
resulting in promoting sprouting angiogenesis in the pres-
ence of VEGF [28]. During kidney development, Ang-1,
Ang-2, and Tie2 are highly expressed and play pivotal
roles in the maturation of glomeruli and renal blood ves-
sels [29].
Recent studies have suggested that AT1R-mediated
signaling induced angiogenesis in hind limb ischemia or
tumor models using AT1aR-deficient mice [30, 31]. Based
on the capacity of Ang II to induce angiogenic changes,
we examined if glomerular capillary area is increased in
the early phase of anti-Thy-1.1 nephritis by infusion of
Ang II initiating 5 days prior to the induction of nephri-
tis, similar to the experiments reported by Wenzel et al
[18]. Since we observed increased glomerular endothe-
lial area in Ang II–infused nephritic rats as compared
to nephritic rats without Ang II infusion, we further in-
vestigated on the level of angiogenesis-associated factors,
VEGF and angiopoietins as well as their receptors. Addi-
tionally, the involvement of AT1R- and AT2R-mediated
signal in this regulatory mechanism was investigated
using receptor selective antagonists. Coordinated regu-
lation of angiogenesis-associated factors by Ang II may
potentially lead to the accelerated recovery of glomerular
endothelial cells in the early phase of anti-Thy-1.1 nephri-
tis model, which is accompanied by glomerular capillary
injury and loss following mesangiolysis [22]. In addition,
glomerular injuries were not exacerbated at the “reso-
lution” phase of anti-Thy-1.1 nephritis in Ang II–infused
rats in spite of persistent hypertension, suggesting the im-
portance of accelerated glomerular capillary repair in the
early stage in this model.
METHODS
Experimental protocol
The experimental protocol was approved by the An-
imal Ethics Review Committee of Okayama University
Graduate School of Medicine, Dentistry, and Pharma-
ceutical Sciences. Studies were performed in male Wistar
rats (CLEA Japan, Tokyo, Japan). The animals had free
access to tap water and standard rat chow. Rats weighing
170 g received continuous infusion of Ang II (170 ng/min)
(Sigma Chemical Co., St. Louis, MO, USA) via subcu-
taneous osmotic minipumps (Alzet model 2002) (Alza
Corp., Palo Alto, CA, USA).
Immune-mediated mesangial cell injury was induced
by the intravenous injection of monoclonal antibody 1-
22-3 (1 mg/rat in 0.5 mL of saline) 5 days after the implan-
tation of minipumps. On day 6, 14, or 35 after the injection
of monoclonal antibody 1-22-3, animals were sacrificed.
In another series of experiments, the following groups
of animals were studied on day 6 after initiating nephri-
tis: (1) normotensive control, (2) normotensive nephritic
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control, (3) Ang II infusion, (4) Ang II infusion with
nephritis, (5) Ang II infusion with nephritis and losar-
tan (30 mg/kg/day by the drinking water) (Merck,
Rahway, NJ, USA), (6) Ang II infusion with nephritis
and PD123319 (0.935 lg/min osmotic minipump) (Sigma
Chemical Co.), and (7) norepinephrine (600 ng/min)
(Sigma Chemical Co.) infusion with nephritis (N = 5 for
each subgroup). No rats have died during the experimen-
tal period. Additionally, some rats were sacrificed at 24
hours following the initiation of anti-Thy-1.1 nephritis to
examine the possible effect of Ang II infusion in the initial
phase of nephritis.
Blood and urine examination
Blood urea nitrogen (BUN), serum and urinary crea-
tinine levels, and urinary total protein levels were mea-
sured by SRL, Inc. (Okayama, Japan). Serum and urinary
creatinine levels were measured by the enzymatic colori-
metric method as described [32]. Urinary total protein
concentration was measured by standard Pyrogallol red
method using MicroTP-AR (Wako Pure Chemical, Os-
aka, Japan). The creatinine clearance was calculated and
expressed as milliliters per minute.
Systolic blood pressure
Arterial blood pressure was measured before the im-
plantation of the osmotic minipumps, induction of the
nephritis and sacrifice using a programmable sphygmo-
manometer (BP-98A) (Softron, Tokyo, Japan) by the tail-
cuff method as described previously [4, 33].
Immunoblot
Immunoblot was performed as previously described
with modifications [18, 34, 35]. Kidney sample was ob-
tained from an individual rat, and five kidneys per group
were employed for analysis by immunoblots. Briefly,
glomeruli were isolated by differential sieving technique
[14] from each kidney, and were resuspended in Laemmli
buffer 1 containing 50 mmol/L Tris-Cl, pH 6.8, and 10%
sodium dodecyl sulfate (SDS). Then, samples were boiled
for 3 minutes and centrifuged at 14,000 rpm for 10 min-
utes at 4◦C. Supernatant was collected and total protein
concentration was determined by using the DC-protein
determination system (Bio-Rad, Hercules, CA, USA) us-
ing bovine serum albumin (BSA) as a standard. To equal
amounts of protein (100 lg), Laemmli buffer 2 containing
dithiothreitol (DTT) (Sigma Chemical Co.), bromphenol
blue (BPB) and glycerol was added to make the final con-
centration of DTT to be 100 lmol/L, that of BPB and
glycerol to be 0.1% and 10%, respectively. Then, sam-
ples were denatured at 100◦C for 7 minutes, and separated
on SDS-polyacrylamide gels (Bio-Rad). Recombinant rat
VEGF164, human Ang-1 and human Ang-2 (R&D Sys-
tems, Minneapolis, MN, USA) were also applied. Samples
were then electrotransferred onto nitrocellulose mem-
branes (Hybond-ECL) (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). The membranes were blocked
with 5% nonfat dry milk in 1× Tris-buffered saline (TBS)
containing 0.1% Tween-20 (TBST), incubated overnight
with rabbit polyclonal anti-Ang-1 (1:1000) (Alpha Diag-
nostics, San Antonio, TX, USA), goat polyclonal anti-
Ang-2 (1:500) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), rabbit polyclonal anti-VEGF (1:1000) (Santa
Cruz Biotechnology), rabbit polyclonal anti-flk-1 (1:100)
(Santa Cruz Biotechnology), rabbit polyclonal anti-flt-1
(1:1000) (Santa Cruz Biotechnology) or rabbit polyclonal
antirat tie2 (1:1000) (kindly provided by Regeneron Phar-
maceuticals, Tarrytown, NY, USA) antibodies at 4◦C.
After incubation with horseradish peroxidase (HRP)-
labeled-secondary antibodies for 1 hour, signals were
detected with enhanced chemiluminescence (ECL) sys-
tem (Amersham Pharmacia Biotech). Membranes were
re-probed with rabbit polyclonal antiactin antibodies
(Bio-Rad) to serve as controls for equal loading. The den-
sity of each band was determined by using NIH image
software, and expressed as a value relative to the den-
sity of the corresponding band obtained from the actin
immunoblot.
Histologic analysis
At 1, 6, 14, and 35 days after the induction of nephritis,
kidneys were removed, fixed in 10% buffered formalin
and embedded in paraffin. Sections (3 lm thick) were
stained with periodic acid-Schiff (PAS) for light micro-
scopic observation. Total glomerular cell number was de-
termined by counting the nuclei within the glomerular
tuft as described [14]. Expansion of the mesangial ma-
trix was quantitated by scoring (grade 0 to 4) using PAS-
stained sections: 0, none; +1, mesangial matrix expansion
observed in less than 25% of the glomerulus; +2, 25% to
50%; +3, 50% to 75%; and +4, greater than 75%. Mesan-
giolysis (day 1 after initiating nephritis) was quantitated
by scoring (grade 0 to 3) using PAS-stained sections as
previously described [24]: 0, no mesangiolysis; +1, seg-
mental mesangiolysis; +2, global mesangiolysis; and +3,
microaneurysm. In each kidney, more than 30 glomerular
cross-sections were examined by two investigators and
averaged. Histologic assessment was performed by the
investigators in a blinded fashion.
Immunohistochemistry
Immunohistochemistry was performed as previously
described [14, 33, 36]. For immunohistochemistry of in-
filtrating monocytes/macrophages, VEGF and Ang-1,
paraffin-embedded sections (3 lm) were used. Sections
were incubated with mouse monoclonal antibody to rat
monocytes/macrophages (clone ED1) (Cymbus Biotech-
nology, Hants, UK), rabbit polyclonal antihuman VEGF
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Fig. 1. Initial histologic changes. An-
giotensin II (Ang II) infusion did not affect
on the initial phase of anti-Thy-1.1 nephritis.
(A) Deposition of mouse Ig in glomeruli
(upper panels). Representative fluorescent
photomicrographs of glomeruli following
immunofluorescence staining for mouse Ig.
Deposition of Ig was detected mainly in
mesangial area in nephritic animals irrespec-
tive of preceding Ang II infusion (original
magnification 200×). Representative light
microscopic appearance of glomeruli (middle
panels) [periodic acid-Schiff (PAS) staining
(original magnification 200×)]. Mesangiol-
ysis (arrowheads) was observed in most of
nephritic glomeruli irrespective of Ang II
infusion similar to control nephritic animals.
Immunofluorescent staining of glomerular
endothelial cells (RECA-1). Representative
fluorescent photomicrographs of glomeruli
following immunofluorescence staining for
RECA-1 (lower panels) (original magni-
fication 200×). (B) Mesangiolysis score.
Mesangiolysis at 24 hours after initiating
nephritis was evaluated as described in the
Methods section (N = 5 for each group).
Each column consists of mean +/− SEM.
Abbreviations are: C, undiseased control; A,
Ang II–infused; T, anti-Thy-1.1 nephritis; AT,
anti-Thy-1.1 nephritis with Ang II infusion.
Each column consists of mean ± SEM.
RECA, rat endothelial cell antigen.
or anti-Ang-1 antibody followed by incubation with bi-
otinylated secondary antibody, and immunoperoxidase
staining was carried out utilizing the Vectastain ABC
Elite Reagent Kit (Vector Laboratory, Burlingame, CA,
USA) [14]. Diaminobenzidine (DAB) was used as a chro-
mogen. All slides were counterstained with hematoxylin.
Normal mouse or rabbit IgG was used as a negative
control.
Immunofluorescence staining for mouse Ig, rat en-
dothelial cell antigen (RECA)-1, and von Willebrand fac-
tor (vWF) was performed using frozen sections. Four mi-
crometer sections were fixed in ethanol, and incubated
with mouse monoclonal anti-RECA-1 antibody (Serotec,
Oxford, UK) or rabbit polyclonal anti-vWF antibody
(Dako, Carpenteria, CA, USA) followed by incuba-
tion with fluorescein isothiocyanate (FITC)-conjugated
secondary antibodies. Frozen sections were incubated
with FITC-conjugated antimouse Ig antibody (Chemi-
con, Temecula, CA, USA) to detect the binding of mon-
oclonal antibody 1-22-3. Sections were observed by a
confocal laser fluorescence microscope (LSM-510) (Carl
Zeiss, Jena, Germany) and obtained image files were then
analyzed using Lumina Vision software (Mitani, Fukui,
Japan) to determine the RECA-1(+) area and vWF(+)
area within glomeruli. In each kidney, more than 20
glomerular cross-sections were examined and averaged.
Statistical analysis
All values are expressed as mean ± SEM. A Kruskal-
Wallis test with post hoc multiple comparisons using the
Scheffe’s test were employed for intergroup comparisons
of clinical parameters and multiple variables. Statistical
analysis was performed by StatView software (Abacus
Concepts, Berkeley, CA, USA). Statistical significance is
presented with P values by a Kruskal-Wallis test repre-
senting overall effect, and P values for post hoc multiple
comparisons between groups by Scheffe’s test. A level of
P < 0.05 was considered statistically significant.
RESULTS
Ang II infusion did not affect on the initial phase of
anti-Thy-1.1 nephritis
Initial histologic changes following the administration
of monoclonal antibody 1-22-3 were examined. At 24
hours after the induction of nephritis, glomerular deposi-
tion of mouse Ig was indistinguishable between rats pre-
treated with Ang II or untreated nephritic control rats
(Fig. 1A). Control nonnephritic kidney section exhibited
no deposition of mouse Ig. Histologic examination of the
kidneys revealed marked mesangiolysis at 24 hours after
the induction of nephritis, and the extent of mesangiolysis
was indistinguishable between rats pretreated with Ang
II or untreated nephritic control rats, suggesting that Ang
II infusion prior to the induction of nephritis did not alter
the initial phase of anti-Thy-1.1 nephritis (Fig. 1). Similar
extent of glomerular endothelial RECA-1(+) area was
observed in Ang II or nephrotic controls and both groups
exhibited slightly diminished appearance as compared to
normal control (Fig. 1A).
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Table 1. Laboratory data of blood and urine samples (time course)
Anti-Thy-1.1 nephritis Anti-Thy-1.1 nephritis with A-II-infusionUndiseased
control Day 6 Day 14 Day 35 Day 6 Day 14 Day 35
Blood urea nitrogen mg/dLd 17.96 ± 0.50 37.88 ± 8.01 25.64 ± 2.09 22.53 ± 1.59 56.38 ± 3.40a 48.98 ± 8.71 36.90 ± 5.50
Serum creatinine mg/dLe 0.22 ± 0.01 0.44 ± 0.05 0.33 ± 0.01 0.30 ± 0.01 0.60 ± 0.05a 0.61 ± 0.12a 0.53 ± 0.05a
Creatinine clearance mL/minf 2.44 ± 0.22 1.07 ± 0.10a 2.39 ± 0.30b 2.83 ± 0.04b 0.56 ± 0.06a 0.98 ± 0.31a,c 0.91 ± 0.26a,c
Daily urinary protein mg/24hoursg 15.49 ± 0.68 85.42 ± 7.30a 53.58 ± 9.67 20.39 ± 0.64b 76.63 ± 9.58a 85.87 ± 17.73a 52.01 ± 5.72
Values are mean ± SEM. Urine samples were collected by placing rats in metabolic cages for 24 hours, N = 5 for each group. Laboratory data on day 6, 14, and 35
after the initiation of nephritis are shown. aP < 0.05 vs. undiseased control; bP < 0.05 vs. anti-Thy-1.1 nephritis on day 6, cP < 0.05 vs. anti-Thy-1.1 nephritis at the same
time points; dP = 0.0001; eP = 0.0001; fP = 0.0001; gP = 0.0001; Kruskal-Wallis test.
Renal function and histologic alterations in time-course
experiment
On day 6 after initiating nephritis, renal dysfunction
and proteinuria were observed in anti-Thy-1.1 nephritis
group, and Ang II infusion exacerbated renal dysfunction
and diminished proteinuria without reaching to statisti-
cal significance (Table 1). Improvement of renal function
and proteinuria was observed in anti-Thy-1.1 nephritis
group on day 14. Although renal function of Ang II–
infused nephritic group tended to be improved on day
14, creatinine clearance was significantly decreased as
compared to nephritis group at this time point. On day
35 at the resolution phase of nephritis, renal function
and proteinuria were markedly improved in anti-Thy-1.1
nephritis group close to the level of undiseased control.
Although renal dysfunction and proteinuria of Ang II–
infused nephritic group tended to be improved on day
35, creatinine clearance was still significantly decreased
as compared to nephritis group at this time point. Ang
II–infused nephritic animals showed comparable eleva-
tion of blood pressure on day 6, 14, or 35 after initiating
nephritis (data not shown).
Control nephritic animals exhibited marked mesan-
gial cell proliferation and matrix expansion at day 6 and
14 after initiating nephritis. These nephritic alterations
were significantly diminished on day 35 (Fig. 2A, C, and
D). Infusion of Ang II markedly ameliorated these alter-
ations at day 6 after initiating nephritis as compared to
control nephritic animals in consistent with the previous
report [18]. On day 14, Ang II–infused nephritic rats ex-
hibited further amelioration of histologic alterations as
compared to control nephritic rats. At this point, histo-
logic alterations in Ang II–infused nephritic rats were
similar to those observed on day 35. There were no sig-
nificant statistical difference of histologic alterations be-
tween Ang II–infused and control nephritic animals on
day 35, both groups showing the appearance of “healing”
of anti-Thy-1.1 nephritis.
We next examined the changes in glomerular endothe-
lial capillary area by immunohistochemistry with anti-
RECA-1 antibody. On day 6 after initiating nephritis,
glomerular RECA-1(+) endothelial area was markedly
reduced in control nephritic animals suggesting insuffi-
cient endothelial cell repair (Fig. 2B and E) in contrast to
Ang II–infused nephritic rats with significant suppression
of the loss in glomerular RECA-1(+) area. On day 14,
glomerular RECA-1(+) area was still greater in Ang II–
infused nephritic animals, and it returned to be equivalent
in both groups on day 35, close to the level of undiseased
control animals.
Changes in blood pressure
Next, we examined the effect of Ang II infusion at day
6 after initiating anti-Thy-1.1 nephritis to further charac-
terize the influence at relatively early stage of nephritis. In
order to assess the specific effect of Ang II independent of
elevated blood pressure, infusion of norepinephrine was
performed on a distinct group of rats followed by the in-
duction of nephritis. Infusion of Ang II or norepinephrine
resulted in increased arterial systolic blood pressure at
the point of initiation of nephritis. Systolic blood pres-
sure was not significantly different between control and
nephritic rats on day 6 after the initiation of nephritis
(Fig. 3B). Ang II–infused nephritic rats exhibited sig-
nificantly elevated systolic blood pressure compared to
nephritic control rats. Treatment with losartan inhibited
the increase of systolic blood pressure induced by Ang
II infusion in nephritic rats in contrast to PD123319 not
showing such an antihypertensive effect. There was no
significant difference in body weight among each group
(data not shown).
Renal function and histologic alterations (day 6)
In Ang II–infused nonnephritic animals, deterioration
of renal function was observed (Table 2) in consistent with
previous report showing decrease of creatinine clearance
following Ang II infusion [37]. Proteinuria was not evi-
dent in Ang II–infused nonnephritic animals in contrast
to the previous report [37] possibly due to the differ-
ence in animal strain (Wistar rat instead of Sprague-
Dawley rat), dosage, or the extended time interval in
the present study. Renal dysfunction of norepinephrine-
infused nephritic rats was similar to that of anti-Thy-
1.1 nephritis group, but exhibited increased proteinuria
compared with anti-Thy-1.1 nephritis or Ang II–infused
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Fig. 2. Angiotensin II (Ang II) infusion ameliorated histologic alterations in anti-Thy-1.1 nephritis without affecting the healing process of nephritis.
(A) Representative light microscopic appearance of glomeruli [periodic acid-Schiff (PAS) staining (original magnification 200×)]. (B) Immunofluo-
rescent staining of glomerular endothelial cells (RECA-1) (original magnification 200×). (C) Matrix score. Control (C) P= 0.012 by Kruskal-Wallis
test; ∗P < 0.05 vs. C; ∗∗P < 0.01 vs. C; #P < 0.05 vs. T6; §P < 0.01 vs. AT6; ‡P < 0.01 vs. T14. (D) Total glomerular cell number per glomerular cross
section. Control (C) P= 0.0054 by Kruskal-Wallis test; ∗P < 0.01 vs. C; #P < 0.05 vs. T6; ##P < 0.01 vs. T6; §P < 0.05 vs. AT6; §P < 0.01 vs. AT6; ‡P <
0.01 vs. T14 (N = 5 for each group). (E) Relative ratio of glomerular RECA-1(+) area. Control (C) P < 0.0001 by Kruskal-Wallis test; ∗P < 0.01 vs.
C; #P < 0.01 vs. T6; §§P < 0.01 vs. AT6; ‡P < 0.01 vs. T14; φP < 0.01 vs. AT14 or T35 (N = 5 for each group). All were determined as described in the
Methods section. Abbreviations are: C, undiseased control; T6, T14, and T35, anti-Thy-1.1 nephritis on day 6, 14, and 35 after induction of nephritis,
respectively; AT6, AT14, and AT35, anti-Thy-1.1 nephritis with Ang II infusion on day 6, 14, and 35 after induction of nephritis, respectively. Each
column consists of mean ± SEM.
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Fig. 3. Angiotensin II (Ang II) infusion ameliorated histologic alterations and the infiltration of monocyte/macrophage in anti-Thy-1.1 nephritis
mainly mediated via angiotensin type 1 receptor (AT1R). (A) Representative light microscopic appearance of glomeruli [periodic acid-Schiff (PAS)
staining (original magnification 200×)]. (B) Systolic blood pressure in experimental groups. Systolic blood pressure in conscious rats was measured
on day 6 after induction of nephritis. Control (C) P = 0.036 by Kruskal-Wallis test; ∗P < 0.05 vs. C, T, or AT + Los. (C) Matrix score. Control (C)
P = 0.0004 by Kruskal-Wallis test; ∗P < 0.01 vs. C or A; #P < 0.05 vs. T; ##P < 0.01 vs. T; §P < 0.01 vs. AT; ‡P < 0.05 vs. AT or AT + Los. (D)
Total glomerular cell number per glomerular cross section. Control (C) P = 0.0044 by Kruskal-Wallis test; ∗P < 0.05 vs. C or A; #P < 0.05 vs. AT
or AT + PD (N = 5 for each group). All were determined as described in the Methods section. (E) Number of mean glomerular ED-1(+) cells per
glomerular cross-section. Control (C) P = 0.002 by Kruskal-Wallis test; ∗P < 0.05 vs. C, A, or AT; #P < 0.05 vs. T; ‡P < 0.05 vs. NT or AT + Los (N
= 5 for each group). Abbreviations are: C, undiseased control, A, Ang II–infused; T, anti-Thy-1.1 nephritis; AT, anti-Thy-1.1 nephritis with Ang II
infusion; NT, anti-Thy-1.1 nephritis with norepinephrine infusion; Los, losartan; PD, PD123319. Each column consists of mean ± SEM.
anti-Thy-1.1 nephritis group. Treatment with losartan re-
sulted in significant improvement of renal dysfunction
and proteinuria as compared to Ang II–infused anti-Thy-
1.1 nephritis group, but treatment with PD123319 failed
to show such remarkable therapeutic effects.
Histologic alterations characterized by mesangial cell
proliferation and matrix expansion were not improved
in norepinephrine-infused nephritic animals in contrast
to Ang II–infused nephritic rats (glomerular cell num-
ber, undiseased control, 53.6 ± 2.9; anti-Thy-1.1 nephritis,
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Table 2. Laboratory data of blood and urine samples from rat
Day 6
Anti-Thy-1.1 Anti-Thy-1.1
nephritis with nephritis with
Norepinephrine Ang II-infusion Ang II-infusion
Control Ang II Thy-1 Ang II+Thy-1 + Thy-1 + losartan + PD123319
Blood urea nitrogen 17.96 ± 0.50 30.18 ± 6.49 37.88 ± 8.01 56.38 ± 3.40a 33.56 ± 5.25 20.26 ± 0.72b 51.00 ± 12.15a,c
mg/dLe
Serum creatinine 0.22 ± 0.01 0.34 ± 0.05 0.44 ± 0.05 0.60 ± 0.05a 0.35 ± 0.03 0.25 ± 0.01b 0.49 ± 0.09
mg/dLf
Creatinine clearance 2.44 ± 0.22 1.16 ± 0.19 1.07 ± 0.10a 0.56 ± 0.06a 1.29 ± 0.07 1.95 ± 0.14b 0.80 ± 0.34a
mL/mng
Daily urinary 15.49 ± 0.68 11.81 ± 2.88a 85.42 ± 7.30a,d 76.63 ± 9.58a,d 145.61 ± 17.69a,b 43.00 ± 8.51b 70.50 ± 15.37a
protein mg/24hoursh
Values are mean ± SEM. Urinary samples were collected by placing rats in metabolic cages for 24 hours (N = 5 for each group). Data on day 6 after the initiation of
nephritis are shown.
aP < 0.05 vs. control; bP < 0.05 vs. Ang II + Thy-1; cP < 0.05 vs. Anti-Thy-1.1 nephritis with Ang II-infusion + losartan; dP < 0.05 vs. Ang II; eP = 0.0001; fP = 0.000;
gP = 0.0001; hP = 0.0001; by Kruskal Wallis test.
118.5 ± 3.8; nephritis with norepinephrine infusion, 119.0
± 1.3; nephritis with Ang II infusion, 86.4 ± 5.5; matrix in-
dex undiseased control, 0.42 ± 0.07; anti-Thy-1.1 nephri-
tis, 3.52 ± 0.06; nephritis with norepinephrine infusion,
3.49 ± 0.12; nephritis with Ang II infusion, 2.30 ± 0.12)
(Fig. 3A, C, and D). Although treatment with losartan
in addition to Ang II infusion exacerbated nephritic al-
terations (glomerular cell number 109.7 ± 2.9, matrix in-
dex; 3.68 ± 0.05, losartan), PD123319-treatment showed
suppressive effect (glomerular cell number 89.2 ± 5.2,
matrix index; 2.87 ± 0.15, PD123319), suggesting that an-
tinephritic effect was mediated mainly via AT1R, and par-
tially via AT2R.
Glomerular accumulation of monocytes/macrophages
We next examined glomerular infiltration by mono-
cytes/macrophages since it is a hallmark of mesangiopro-
liferative glomerulonephritis [38]. Marked glomerular
accumulation of ED-1–positive monocyte/macrophage
was observed in nephritic rats (Fig. 3E). Infusion of
Ang II significantly decreased the influx of mono-
cyte/macrophage, although norepinephrine infusion did
not show such inhibitory effect (control 1.6 ± 0.4, nephri-
tis 16.0 ± 1.8, nephritis with norepinephrine infusion 13.2
± 0.7, and nephritis with Ang II infusion 4.3 ± 0.4). Sup-
pression of monocyte/macrophage recruitment following
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→
Fig. 4. Angiotensin II (Ang II) induces glomerular capillary repair through angiotensin type 1 and type 2 receptor (AT1R and AT2R). (A)
Immunofluorescence staining of glomerular endothelial cells (RECA-1). Glomerular endothelial cell damage and recovery were assessed by
indirect immunofluorescence method using anti-RECA-1 antibody as described in the Methods section. (B) Glomerular RECA-1(+) area was
determined by using image analyzer (Lumina Vision) as described in the Methods section. Relative ratio of glomerular RECA-1(+) area. Control
(C) P = 0.0087 by Kruskal-Wallis test; ∗P < 0.05 vs. C or A; #P < 0.05 vs. AT. (C) Immunofluorescence staining of glomerular endothelial cells
[von Willebrand factor (vWF)]. Immunofluorescence staining was performed using anti-vWF antibody as described in the Methods section. (D)
Glomerular vWF-positive area was determined by using image analyzer (Lumina Vision) as described in the Methods section. Relative ratio of
glomerular vWF-positive area. Control (C) P = 0.0002 by Kruskal-Wallis test; ∗P < 0.01 vs. C, A, or AT. Each column consists of mean ± SEM (N
= 5 for each group). Abbreviations are: C, undiseased control; A, Ang II–infused; T, anti-Thy-1.1 nephritis; AT, anti-Thy-1.1 nephritis with Ang II
infusion; NT, anti-Thy-1.1 nephritis with norepinephrine infusion; Los, losartan; PD: PD123319 (original magnification 400×).
Ang II infusion was inhibited by losartan, but not by
PD123319 (losartan 11.8 ± 0.7 and PD123319 6.6 ± 0.2),
suggesting that the inhibitory effect on monocyte accu-
mulation was mainly mediated via AT1R, and partially via
AT2R.
Ang II suppresses the loss of glomerular capillary area
dependent on both AT1R and AT2R in the early phase
of anti-Thy-1.1 nephritis
The specific effect of Ang II to suppress the loss in
glomerular endothelial capillary area was determined by
immunohistochemical detection of RECA-1. Although
Ang II infusion resulted in the suppression of the loss in
glomerular endothelial area in nephritic animals on day
6, norepinephrine infusion failed to show such an effect.
The effect of Ang II infusion on maintaining glomeru-
lar endothelial area was equally suppressed by losar-
tan and by PD123319 (Fig. 4A and B). To further sup-
port the effect of Ang II infusion in suppressing the loss
of glomerular capillary area in the early phase of anti-
Thy-1.1 nephritis, we also examined immunostaining for
vWF [39]. Immunoreactivity for vWF was dominantly ob-
served in glomerular capillary area in normal control and
Ang II–infused control rats. Immunoreactivity for vWF
was maintained in Ang II–infused nephritic rats in par-
allel with results observed in RECA-1 immunostaining
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(Fig. 4C and D). Suppressive effect of Ang II infusion on
the loss in vWF immunoreactivity was inhibited by treat-
ment with losartan or PD123319. Combining these results
obtained from RECA-1 and vWF immunostaining, the
effect of Ang II in suppressing the loss in glomerular cap-
illary area was considered to be mediated via both AT1R
and AT2R.
Immunohistochemical analysis of glomerular VEGF
expression
We next examined glomerular expression of
angiogenesis-associated factors, VEGF and Ang-1,
considering the effect of Ang II to increase glomerular
endothelial cell area potentially through regulating the
expression of these factors. In glomeruli of undiseased
normal rats, VEGF was detected on glomerular capillar-
ies, most likely on podocytes based on the distribution
pattern (Fig. 5A). In nephritic control rats, VEGF was
observed in mesangial area and on podocytes, and Ang
II infusion further increased the expression of VEGF
mainly on podocytes and less markedly in mesangial
area (Fig. 5A). The glomerular immunoreactivity for
VEGF was partially diminished in losartan-treated rats,
but not in PD123319-treated rats.
Expression of VEGF and receptors, flk-1 and flt-1
The expression of VEGF, and receptors, flk-1, flt-
1 in glomeruli, was further examined by immunoblot.
Although Ang II infusion alone only showed modest in-
crease of VEGF as compared to normal control, the ex-
pression of VEGF was significantly increased in nephritic
rats (Fig. 5B to E). The level of VEGF was elevated by
norepinephrine infusion (2.4-fold), and further increased
by 3.4-fold in Ang II–infused nephritic rats. Increase
in the protein level of VEGF induced by Ang II infu-
sion was partially blocked by losartan (62.6% inhibition),
or PD123319 (43.1% inhibition), suggesting the involve-
ment of both receptors. The glomerular expression of flk-
1, a high affinity receptor of VEGF, was induced by Ang
II infusion in control rats and in nephritic rats (4.2-fold
increase). The level of glomerular flk-1 was also increased
in nephritic control rats (Fig. 6A and C). Increase in the
level of flk-1 induced by Ang II infusion was blocked by
losartan and by PD123319, suggesting the involvement
of AT1R and AT2R. The protein level of flt-1, a low-
affinity receptor for VEGF, was also increased by Ang II
infusion in nephritic rats (1.8-fold increase). Increase in
the level of flt-1 induced by Ang II infusion was partially
blocked by losartan or PD123319, suggesting the role of
both AT1R and AT2R (Fig. 6A and B). These results in-
dicate that Ang II infusion induced VEGF expression
mainly from podocytes and mesangial cells, and induced
the expression of flk-1 and flt-1 most likely on glomerular
endothelial cells, thus facilitating the promotion of angio-
genic response in glomeruli.
Immunohistochemical analysis of glomerular Ang-1
expression
The immunoreactivity for Ang-1 was mainly detected
on podocytes in normal control rats, and Ang II infusion
markedly increased immunoreactivity for Ang-1 protein
on podocytes (Fig. 7A). Increased immunoreactivity for
Ang-1 was observed in Ang II–infused nephritic ani-
mals, but not in norepinephrine-infused nephritic animals
suggesting the specific effect of Ang II independent of
elevated blood pressure (Fig. 7A). The glomerular im-
munoreactivity for Ang-1 was diminished in losartan-
treated or PD123319-treated rats as compared to Ang
II–infused nephritic rats (Fig. 7A).
Expression of Ang-1, Ang-2, and tie2
The glomerular expression of Ang-1 was markedly in-
creased (3.3-fold) in Ang II–infused nonnephritic rats as
compared to normal control. The level of Ang-1 was also
significantly increased in nephritic control rats, and Ang
II further induced (3.6-fold) the expression of Ang-1 in
nephritic rats (Fig. 7B to E). The increase of Ang-1 pro-
tein induced by Ang II was almost completely blocked
by losartan (94.0% inhibition), and markedly blocked
by PD123319 (78.3% inhibition), suggesting the involve-
ment of both AT1R and AT2R. In contrast, Ang-2, an en-
dogenous antagonist of Ang-1, was suppressed by Ang II
infusion in nonnephritic rats as compared to normal con-
trol rats (P < 0.01). The protein level of Ang-2 in Ang II–
infused nephritic rats was significantly lower than normal
control or nephritic control rats (P < 0.05). Infusion of
norepinephrine resulted in a moderate reduction of Ang-
2 protein level in nephritic animals. Treatment with losar-
tan (2.3-fold) or PD123319 (2.1-fold) increased the level
of Ang-2 as compared to Ang II–infused nephritic rats
suggesting the role of both AT1R- and AT2R-mediated
signal on the inhibition of Ang-2 expression (Fig. 8A to
D). The expression of receptor tie2 was not significantly
altered in control nephritic rats compared to normal con-
trol rats (P < 0.05). The expression of tie2 was markedly
induced by Ang II infusion (1.9-fold increase), but not
significantly by norepinephrine infusion in nephritic rats.
Increase in the level of tie2 protein induced by Ang II
infusion was significantly blocked by PD123319, but not
by losartan, suggesting the dominant role of AT2R over
AT1R (Fig. 8E to H). Accordingly, Ang II infusion re-
sulted in the increase of Ang-1/Ang-2 ratio and tie2, thus
conceivably leading to “stable” vascular microenviron-
ment resistant to inflammatory stimuli as well as reduced
monocyte/macrophage infiltration.
DISCUSSION
Angiogenesis is composed of several steps: (1) the
degradation of vascular basement membrane matrix by
protease, (2) migration and proliferation of endothe-
lial cells, (3) endothelial tube formation, (4) recruitment
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Fig. 5. Angiotensin II (Ang II) infusion induces glomerular vascular endothelial growth factor (VEGF) expression. (A) Immunohistochemistry
of VEGF. Distribution of VEGF was determined as described in the Methods section by indirect immunohistochemistry. VEGF was observed in
glomerular podocytes (arrows) and in mesangial area (arrowheads). Representative light microscopic appearance of glomerulus (original magni-
fication 400×). (B) Immunoblot analysis of VEGF (30 kD). (C) Immunoblot analysis for actin (42 kD). In each lane, 100 lg of protein obtained
from isolated glomeruli was loaded. The band of recombinant rat VEGF164 (rrVEGF) was observed around 30 kD in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Each band was scanned and subjected to densitometry. (D) Intensities of VEGF protein relative
to actin. Control (C) P < 0.0001 by Kruskal-Wallis test; ∗P < 0.05 vs. C; #P < 0.01 vs. C, A, or T; §P < 0.05 vs. AT. (E) Intensities of VEGF protein
relative to actin. Control (C) P = 0.0222 by Kruskal-Wallis test; ∗P < 0.05 vs. AT. Abbreviations are: C, undiseased control; A, Ang II–infused; T,
anti-Thy-1.1 nephritis; AT, anti-Thy-1.1 nephritis with Ang II infusion; NT, anti-Thy-1.1 nephritis with norepinephrine infusion; Los, losartan; PD,
PD123319 (N = 5 for each group). Each column consists of mean ± SEM.
and attachment of mesenchymal cells to the endothe-
lial cell tube, and (5) maturation of blood vessels [19].
The essential role of VEGF in the development of re-
nal vasculatures and glomeruli had been reported [40],
and VEGF also plays an important role in glomerular
capillary repair in nephritis model [24, 41]. The role of
Ang-1, Ang-2, and tie2 in the process of renal develop-
ment is well-known, and the loss of VEGF and Ang-1
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Fig. 6. Immunoblot analysis of Flt-1 and Flk-1. (A) Immunoblots for
Flt-1 (170 kD), Flk-1 (160 kD) and actin. In each lane, 100 lg of protein
obtained from isolated glomeruli was loaded. Each band was scanned
and subjected to densitometry. (B) Intensities of Flt-1 protein relative
to actin. Control (C) P = 0.0062 by Kruskal-Wallis test; ∗P < 0.05 vs. C;
#P < 0.05 vs. AT; ‡P < 0.05 vs. AT + Los or AT + PD. (C) Intensities
of Flk-1 protein relative to actin. Control (C) P = 0.0054 by Kruskal-
Wallis test; ∗P < 0.05 vs. C or AT + PD; #P < 0.05 vs. AT; ‡P < 0.05 vs.
AT + Los. Two bands were observed around 160 kD in immunoblots
for Flk-1. Abbreviations are: C, undiseased control; A, angiotensin II
(Ang II)–infused; T, anti-Thy-1.1 nephritis; AT, anti-Thy-1.1 nephritis
with Ang II infusion; Los, losartan; PD, PD123319 (N = 4 for each
group). Each column consists of mean ± SEM.
accompanied by the up-regulation of Ang-2 had been ob-
served in anti-glomerular basement membrane (GBM)
nephritis model in a temporal manner in association with
glomerular capillary loss [42].
In the present study, we observed that Ang II infusion
resulted in the amelioration of characteristic histologic
features in rat anti-Thy-1.1 nephritis model similar to
the previous report [18]. The surprising effect of Ang
II infusion in ameliorating early changes in anti-Thy-
1.1 nephritis is in contrast to previous studies that de-
scribed the beneficial effect of blockade of the RAS
in renal disorders [16, 17]. However, we speculate the
milieu caused by the infusion of exogenous Ang II is con-
siderably apart from the interference with a local endoge-
nous RAS by angiotensin-converting enzyme (ACE)
inhibitor or AT1RA. In addition, the essential role of the
RAS in renal vascular development and maintenance of
blood vessels had also been reported [5–7]. Studies us-
ing mice deficient in both AT1aR and AT1bR revealed
delayed maturity in glomerular growth and renal arte-
rial hypertrophy [6, 7]. More recently, SHRs treated with
ACE inhibitor or AT1RA from the last week of gestation
until 8 weeks of age exhibited smooth muscle cell hyper-
plasia and increased wall thickness in renal cortical ar-
teries, ultimately resulting in malignant hypertension [9].
These previous studies may suggest that the blockade of
Ang II formation and AT1R-mediated actions suppress
the synthesis of Ang II–induced another trophic factors
essential for the development and maintenance of renal
vascular structures. We speculate VEGF and Ang-1 may
be such trophic factors induced by Ang II mediating ac-
celerated glomerular endothelial cell repair in the early
phase of anti-Thy-1.1 nephritis. In addition, activation of
the RAS might possess beneficial effects on kidney in
certain pathophysiologic conditions such as renal artery
stenosis [10] and partial urinary tract obstruction [11].
In the present study with extended time points, Ang
II infusion neither resulted in the exacerbation of his-
tologic alterations nor interfered with healing process
of anti-Thy-1.1 nephritis. Previous study of two-kidney,
one-clip hypertension rat model followed by the induc-
tion of anti-Thy-1.1 nephritis revealed no significant in-
fluence of renovascular hypertension on healing of the
glomerular lesions [43]. Since two-kidney, one-clip Gold-
blatt hypertension model is an Ang II–dependent model
of hypertension, our results may be considered to share
consistency with these previous findings. Although re-
nal function tended to be impaired in Ang II–infused
nephritic animals as compared to control nephritic an-
imals, histologic alterations were less remarkable in Ang
II–infused animals. Previous report by Aizawa et al [37]
demonstrated that infusion of Ang II for a shorter term
(7 days) in Sprague-Dawley rats decreased glomerular fil-
tration rate (GFR) (as demonstrated by creatinine clear-
ance) and increased proteinuria [37]. They described that
AT1R-mediated action of Ang II was responsible for
the decrease of creatinine clearance, whereas the syn-
ergistic action of Ang II and pressor overload was crit-
ical for the increased proteinuria. Decreased creatinine
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Fig. 7. Angiotensin II (Ang II) infusion induces glomerular angiopoeitin-1 (Ang-1) expression. (A) Immunohistochemistry of Ang-1. Distribution
of Ang-1 was determined as described in the Methods section by indirect immunohistochemistry. Ang-1 was observed in glomerular podocytes
(arrowheads) and less frequently in mesangial area. Representative light microscopic appearance of glomerulus (original magnification 400×).
Immunoblot analysis of Ang-1. (B and C) Immunoblots for Ang-1 (100 kD, most likely presenting as dimer) and actin. In each lane, 100 lg of
protein obtained from isolated glomeruli was loaded. Recombinant human Ang-1 (rhAng-1) migrated as an approximately 70 kD bands in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Each band was scanned and subjected to densitometry. (D) Intensities of Ang-1
protein relative to actin. Control (C) P = 0.0001 by Kruskal-Wallis test; ∗P < 0.01 vs. C; #P < 0.01 vs. A or AT. (E) Intensities of Ang-1 protein
relative to actin. Control (C) P = 0.0009 by Kruskal-Wallis test. ∗P < 0.01 vs. AT. Abbreviations are: C, undiseased control; A, Ang II–infused; T,
anti-Thy-1.1 nephritis; AT, anti-Thy-1.1 nephritis with Ang II infusion; NT, anti-Thy-1.1 nephritis with norepinephrine infusion; Los, losartan; PD,
PD123319 (N = 5 for each group). Each column consists of mean ± SEM.
clearance levels in Ang II–infused nephritic animals as
compared to control nephritic rats in the present study are
in line with this previous observation. Proteinuria tended
to be exacerbated in Ang II–infused animals on day 14
and 35, but was slightly diminished on day 6 as compared
to control nephritic rats, possibly due to reduced GFR
at the proteinuric stage. We failed to observe proteinuria
in Ang II–infused nonnephritic animals possibly due to
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Fig. 8. Immunoblot analysis of angiopoeitin-2 (Ang-2) and tie2. (A and B) Immunoblots for Ang-2 (50 kD) and actin are shown. In each lane,
100 lg of protein obtained from isolated glomeruli was loaded. Recombinant human Ang-2 (rhAng-2) migrated as an approximately 60 kD bands
in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Each band was scanned and subjected to densitometry. (C) Intensities
of Ang-2 protein relative to actin (N = 5 for each group). Control (C) P = 0.0004 by Kruskal-Wallis test; ∗P < 0.01 vs. C; #P < 0.05 vs. T. (D)
Intensities of Ang-2 protein relative to actin (N = 5 for each group). Control (C) P = 0.0033 by Kruskal-Wallis test; ∗P < 0.01 vs. AT. Each column
consists of mean ± SEM. (E) Immunoblots for tie2 (140 kD) and actin. In each lane, 100 lg of protein obtained from isolated glomeruli was loaded.
Each band was scanned and subjected to densitometry. (F) Immunoblots for tie2 (140 kD) and actin. In each lane, 100 lg of protein obtained from
isolated glomeruli was loaded. Each band was scanned and subjected to densitometry. (G) Intensities of tie2 protein relative to actin. Control (C)
P < 0.0001 by Kruskal-Wallis test; ∗P < 0.01 vs. C, A or T. (H) Intensities of tie2 protein relative to actin. Control (C) P = 0.0032 by Kruskal-Wallis
test; ∗P < 0.01 vs. AT or AT + Los. Abbreviations are: C, undiseased control; A, angiotensin II (Ang II)–infused; T, anti-Thy-1.1 nephritis; AT,
anti-Thy-1.1 nephritis with Ang II infusion; NT, anti-Thy-1.1 nephritis with norepinephrine infusion; Los, losartan; PD, PD123319 (N = 5 for each
group). Each column consists of mean ± SEM.
the different strains of animals used in the present study
or distinct time course. Norepinephrine served as con-
trols for Ang II showing comparable elevation of systolic
blood pressure. Creatinine clearance of norepinephrine-
infused nephritic rats was close to that of control nephritic
rats, and Ang II–infused nephritic rats exhibited signifi-
cant deterioration. Treatment with losartan markedly im-
proved creatinine clearance of Ang II–infused nephritic
animals in contrast to PD123319 lacking such effects. Al-
though the experimental settings are different between
the present study and the previous study by Aizawa et al
[37], these results again suggest that Ang II infusion de-
creases creatinine clearance via AT1R-mediated action.
Collectively, the discrepancy between renal function and
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histologic findings observed in the present study may, at
least in part, depend upon the direct role of Ang II in-
fusion on GFR. Proteinuria in norepinephrine-infused
nephritic rats was increased as compared to nephritic con-
trol rats. Treatment with losartan significantly improved
proteinuria of Ang II–infused nephritic animals in con-
trast to PD123319 lacking such effects. These results again
suggest the involvement of Ang II (mainly via AT1R) and
pressor load on proteinuria.
Although Ang II infusion ameliorated increase of
glomerular cellularity and the expansion of mesan-
gial matrix, norepinephrine failed to show such effects.
Our results are in consistent with previous reports by
Wenzel et al, using antithymocyte serum–induced nephri-
tis and antithymocyte serum nephritis with renovascu-
lar hypertension [18, 44]. These findings indicate that
elevated blood pressure did not ameliorate nephritic al-
terations, but this effect was attributable to the specific
action of Ang II. The glomerular accumulation of mono-
cyte/macrophage is one of the common pathologic find-
ings in various forms of glomerular disorders. Previous
report demonstrated the Ang II–induced decrease of
monocyte/macrophage mediated by the suppression of
MCP-1 at 24 hours after the induction of antithymo-
cyte serum nephritis [18]. We observed that Ang II infu-
sion suppressed the glomerular accumulation of mono-
cyte/macrophage on day 6 after initiating nephritis. This
effect was mainly dependent on AT1R, similar to the pre-
vious study [18]. Although it is hard to assess the rea-
son why we could observe the inhibitory effect of Ang II
on day 6, we speculate the discrepant findings might be
partly attributable to the difference in disease models (us-
ing monoclonal 1-22-3 antibody in the present study in-
stead of antithymocyte serum) or to the difference in the
genetic background of rats (using Wistar rats instead of
Sprague-Dawley rats). Infusion of norepinephrine failed
to show inhibitory effect on monocyte/macrophage re-
cruitment, again suggesting the effect of Ang II inde-
pendent of blood pressure. Similarly, Ang II–induced
suppression of mesangial matrix expansion was domi-
nantly mediated via AT1R. We speculate that reduced
infiltration of monocyte/macrophage in Ang II–infused
nephritic rats may, at least in part, account for the re-
duction in the accumulation of mesangial matrix, since
chemokines produced by monocyte/macrophage are in-
volved in the accumulation of ECM [45].
In the present study, we used immunostaining for
RECA-1 and vWF to determine the glomerular capillary
endothelium, and rats with anti-Thy-1.1 nephritis exhib-
ited marked reduction in the level of these endothelial
cell markers in consistent with previous report showing
similar reduction in the number of glomerular capillary-
lumina at the early stage of anti-Thy-1.1 nephritis [23].
Deposition of Ig as well as mesangiolysis in the initial
phase of anti-Thy-1.1 nephritis were similarly observed
in Ang II–infused and control nephritic animals, suggest-
ing that Ang II did not influence on the initial alterations
in the course of anti-Thy-1.1 nephritis. Treatment with
Ang II resulted in the suppression of the loss in RECA-
1- and vWF-positive area suggesting that Ang II infusion
caused accelerated recovery of glomerular endothelial
cells following loss of endothelial cells caused by the lack
of capillary support due to mesangiolysis [22]. The ef-
fect of Ang II to maintain glomerular endothelial area in
the early stage of anti-Thy-1.1 nephritis was mediated
via both AT1R and AT2R. Suppression of the loss in
glomerular capillary area in Ang II–infused nephritic an-
imals in the early stage might have lead to the accelerated
healing of nephritic alterations on day 14.
Recent reports clarified the involvement of Ang II in
inducing angiogenesis in various setting of diseases. Ang
II induced VEGF and Ang-2, and stimulated angiogen-
esis via AT1R in cardiac microvascular endothelial cells
[46]. In AT1a knockout mice, suppressed angiogenic re-
sponse to ischemic injury was observed [30]. AT2R neg-
atively modulated ischemia-induced angiogenesis using
AT2R-deficient mice [47]. These reports indicated the in-
volvement of Ang II in inducing angiogenesis mainly via
AT1R. However, recent report demonstrated the possi-
ble action of AT2R in inducing angiogenesis using algi-
nate implant angiogenesis model in AT2R-deficient mice
[48]. In diabetic retinopathy model and Ang II infu-
sion model, increased retinal expression of VEGF was
blocked with AT1RA or PD123319 [49].
Our present results demonstrated that the protein level
of VEGF was significantly elevated in control nephritic
rats compared to normal control animals. Several growth
factors and cytokines such as TGF-b , PDGF, Ang II,
interleukin (IL)-1 and IL-6, are known to up-regulate
VEGF expression [50]. The observed elevation in the
level of VEGF in control nephritic rats may be attributed
to the effects caused by these factors, at least in part,
since some of these factors are considered to be increased
in anti-Thy-1.1 nephritis. Ang II infusion markedly in-
duced VEGF protein level compared to control nephritic
rats, and norepinephrine also induced VEGF to a lesser
extent. Previous reports demonstrated the involvement
of mechanical stretch in inducing VEGF [51]. Our re-
sults may suggest that systemic hypertension induced
by norepinephrine infusion might have resulted in up-
regulation of VEGF possibly mediated via mechanical
stretch. Up-regulation of VEGF induced by Ang II infu-
sion was inhibited by losartan, but not by PD123319, sug-
gesting the involvement of AT1R similar to the reported
results on mesangial cells [51]. Recent study demon-
strated that Ang II infusion up to 2 weeks resulted in
increased expression of VEGF protein, and that AT1RA
(valsartan) moderately suppressed VEGF production, in
contrast to PD123319 almost completely blocking Ang
II–induced increase of VEGF [52]. First, we speculate
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the involvement of distinct regulatory system in different
two disease models resulted in the discrepancy between
two studies. Second, since we obtained cell lysates from
isolated glomeruli, our results precisely reflected the al-
terations in glomeruli distinct from results obtained by
utilizing whole kidney sample [52], considering that re-
nal tubular epithelial cells and macrophages also produce
VEGF [53].
The protein level of flk-1 was increased in Ang
II–infused control, nephritic control and Ang II–
infused nephritic rats. Previous reports demonstrated
up-regulated kinase domain region (KDR) and flt-1 ex-
pression in glomeruli of human mesangioproliferative
glomerulonephritis [54] and increased expression of flk-
1 in association with glomerular endothelial cell growth
and thus capillary repair in anti-Thy-1.1 nephritis [55].
Up-regulation of flk-1 as well as flt-1 in nephritic con-
trol rats thus may suggest the mechanism in relation to
glomerular capillary repair. Infusion of Ang II resulted
in further increase of flk-1 and flt-1 in nephritic rats as
compared to nephritic control or Ang II–infused control
rats. Up-regulation of flt-1 and flk-1 in Ang II–infused
nephritic rats was mediated via both AT1R and AT2R.
We also examined changes in the expression of Ang-
1 and Ang-2, since angiopoietins play crucial roles in
the process of angiogenesis and vascular maturation.
The level of Ang-1 protein was significantly increased
in anti-Thy-1.1 nephritis compared to normal control
rats. Although not described previously in the setting of
anti-Thy-1.1 nephritis, the increase in the level of Ang-
1 together with the increased VEGF/flk-1/flt-1 expres-
sion suggest the self-protective mechanism to promote
angiogenic repair against glomerular capillary injury in
the early phase of nephritis. The level of Ang-1 protein
was also increased in glomeruli of Ang II–infused control
and nephritic rats (approximately threefold). In contrast
to norepinephrine infusion, Ang II infusion showed sig-
nificantly increased Ang-1 suggesting the role of Ang II in
inducing Ang-1 independent of elevated blood pressure.
In previous report by Rizkalla et al [52], Ang II infusion
resulted in the increase of Ang-1 protein (approximately
twofold) mediated via AT1R [52]. In our experiments,
both AT1R and AT2R were involved in inducing Ang-1.
The observed discrepancy in the extent of increase in the
level of Ang-1 following Ang II infusion and the reper-
toire of responsible Ang II receptors might be explained
again by the distinct materials (i.e., glomeruli vs. whole
kidney) used in obtaining protein extracts, and by dis-
tinct disease models employed. The expression of Ang-
2 was suppressed by Ang II infusion in control rats. In
contrast, results reported by Rizkalla et al [52] showed
up-regulation of Ang-2 following Ang II infusion, again
considered to be attributable to the absent glomerular
isolation step in their experiments, potentially suggesting
increased production of Ang-2 in extraglomerular cells
following Ang II infusion. Infusion of norepinephrine
in nephritic rats resulted in the decrease of glomerular
Ang-2 protein level, suggesting the inhibitory mecha-
nism induced by elevated blood pressure. However, re-
sults obtained by using receptor antagonists revealed that
PD123319 treatment exhibiting similar extent of systemic
hypertension with Ang II–infused nephritic rats, failed
to down-regulate Ang-2, suggesting that the inhibitory
mechanism on Ang-2 expression following Ang II infu-
sion was independent of elevated blood pressure. The in-
hibitory effect of Ang II on the expression of Ang-2 was
considered to be mediated via both AT1R and AT2R in
anti-Thy-1.1 nephritis rats. The expression of tie2 was not
significantly altered in Ang II–infused control and con-
trol nephritic rats as compared to normal control rats.
Although infusion of norepinephrine showed similar re-
sults, Ang II infusion markedly increased tie2 expression
in nephritic rats compared to other controls. The effect of
Ang II in increasing the level of tie2 protein was mainly
mediated via AT2R. These results implicate that Ang II
infusion increased the relative ratio of Ang-1/Ang-2 and
the expression of tie2 in anti-Thy-1.1 nephritis, and thus
triggering the signal mediated by Ang-1/tie2 system. This
regulatory mechanism on the expression of Ang-1/Ang-
2/tie2 was mediated via both AT1R and AT2R.
Although both VEGF and Ang-1/tie2 are essential fac-
tors for vascular development and angiogenesis, the ap-
propriate balance between these factors are considered to
be very important for proper formation of blood vessels.
Thurston et al [56] reported the formation of leaky blood
vessels in mice overexpressing VEGF, and the develop-
ment of nonleaky blood vessels in mice overexpressing
Ang-1, and that coexpression of Ang-1 and VEGF re-
sulted in enhanced angiogenic effect with the formation
of nonleaky blood vessels. We recently reported that the
increase of VEGF and Ang-2 in the model of diabetic
nephropathy had been inhibited by tumstatin peptide,
an angiogenesis inhibitor derived from type IV collagen,
accompanied by therapeutic effects [35]. In the present
study, Ang II induced signaling via VEGF/flk-1/flt-1 and
Ang1/tie2 in the early phase of anti-Thy-1.1 nephritis
following glomerular endothelial cell damage, suggest-
ing the orchestrated environment toward promoting an-
giogenesis, potentially leading to the formation of non-
leaky blood vessels. We consider this microenvironment
resulted in the accelerated recovery of glomerular cap-
illary structures in Ang II–infused nephritic rats. Addi-
tionally, decreased infiltration of monocyte/macrophage
in Ang II–infused nephritic rats may be attributed to
the formation of nonleaky glomerular capillaries in the
presence of enhanced Ang-1/tie2 system accompanied
by up-regulation of VEGF. Ang-1 stabilizes blood ves-
sels rendering them nonleaky to inflammatory insult by
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inducing the attachment of pericytes (mesenchymal cells)
around endothelial cell tube. In the setting of glomerular
capillary microenvironment, mesangial cells may be con-
sidered to act like pericytes since they provide support for
maintaining glomerular capillary structures. Coordinated
up-regulation of VEGF and Ang-1 by Ang II infusion
initiated prior to the induction of nephritis might have
mediated glomerular endothelial cell repair in a “stable”
manner, and thus, at least in part, resulted in the stabi-
lization of mesangial cells with the amelioration of pro-
liferative and fibrogenic changes in the early phase of
anti-Thy-1.1 nephritis. Although we could not observe
significant exacerbation of tubulointerstitial injuries in
Ang II–infused nephritic rats compared to nephritic con-
trol rats, a previous report by Wenzel et al [18] described
the observed tubulointerstitial lesion in this model simi-
lar to previously described focal tubulointerstitial injuries
induced by Ang II infusion for longer time [57].
According to the results obtained by immunohisto-
chemistry of VEGF and Ang-1, both of these factors
were mainly localized to glomerular podocytes. The cru-
cial role of glomerular podocytes had been demonstrated
in the recovery phase of anti-Thy-1.1 nephritis. Signals
from podocytes are considered to attract the sprouting of
capillaries to sites beneath the GBM, because at the sites
forming an adhesion to Bowman’s capsule and at which
the GBM was devoid of podocytes, capillaries never as-
sembled [22]. Our results suggest that Ang II stimulated
the production of VEGF and Ang-1 in podocytes and
increased the expression of flk-1, flt-1 and tie2 on
glomerular endothelial cells, properly orchestrating the
angiogenic capillary repair process. Also, the indirect in-
fluence of glomerular endothelial cells toward glomerular
podocytes possibly mediated via secreted factors or alter-
ation on matrix microenvironment might be involved in
the ameliorated glomerular changes in Ang II–infused
anti-Thy-1.1 nephritis rats in the early phase. Mice with
podocyte-specific overexpression or deletion of VEGF
demonstrated the development of proteinuria and patho-
logic changes in glomerular endothelial cells, suggest-
ing the importance of appropriate level of VEGF in
maintaining intact glomerular capillary structures [58].
The suggested role of Ang-1 in maintaining glomeru-
lar endothelium and regulating the action of VEGF on
glomerular permselectivity [59] further support the im-
portance of interaction between glomerular endothelial
cells and podocytes in the repair and the maintenance of
glomerular capillary structures.
CONCLUSION
We demonstrated that Ang II infusion initiated prior to
the induction of anti-Thy-1.1 nephritis suppressed char-
acteristic histologic alterations as previously described
by Wenzel et al, induced the increase of glomerular en-
dothelial cell area possibly in association with the induc-
tion of angiogenic factors such as VEGF and Ang-1 and
their receptors. Our results further suggested the accel-
erated histologic healing process of nephritic alterations
in Ang II–infused animals potentially due to the increase
of endothelial area in the early stage of nephritis. The
specific setting utilized in the present study revealed un-
known biological function of Ang II in association with
angiogenic response in glomeruli, similar to the reported
proangiogenic effect of Ang II on extrarenal blood ves-
sels [30, 46]. Our results however do not question the well-
established beneficial effect of ACE inhibitors or AT1R
blocker in “chronic” renal disorders in physiological set-
tings. Further clarification of downstream signaling path-
ways involved in the regulation of VEGF, Ang-1, Ang-2,
and flk-1/flt-1/tie2 receptors mediated by AT1R or AT2R
stimulation may lead to the development of novel specific
therapeutic approaches to promote glomerular capillary
repair.
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